ClinicalTrials.gg
RecruitingNCT04775485FIREFLY-1Updated Apr 10, 2025

A Study to Evaluate Tovorafenib in Pediatric and Young Adult Participants With Relapsed or Progressive Low-Grade Glioma and Advance Solid Tumors

A Phase 2 interventional study of Tovorafenib in Low-grade Glioma and Advanced Solid Tumor, sponsored by Day One Biopharmaceuticals, Inc.. Recruiting at 35 sites in 11 countries. Open to participants aged 6 Months to 25 Years. Per ClinicalTrials.gov, last updated 2025-04-10.

Sponsored by Day One Biopharmaceuticals, Inc. · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Apr 2021; still recruiting 5 years 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
141
Allocation
Non-randomized
Ages
6 Months to 25 Years
Sex
All
01

Study summary

This is a Phase 2, multi center, open-label study to evaluate the safety and efficacy of Type II RAF (tovorafenib) in pediatric participants with low-grade glioma or advanced solid tumors. Qualifying genomic alterations will be identified through molecular assays as routinely performed at Clinical Laboratory Improvement Amendments (CLIA) of 1988 or other similarly certified laboratories prior to enrollment into any of the arms. The study will consist of a screening period, a treatment period, a long-term extension phase, end of treatment (EOT) visit(s), a safety follow-up visit, and long-term follow-up assessments.

02

Conditions studied

  • Low-grade Glioma
  • Advanced Solid Tumor

Keywords

  • Low-grade Glioma
  • Advanced Solid Tumor
  • FIREFLY-1
  • DAY101
  • Tovorafenib
03

In context

Lead sponsor

Day One Biopharmaceuticals, Inc. is the lead sponsor of 8 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
6 Months to 25 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Low Grade Glioma \& Low-Grade Glioma Extension: a or progressive LGG with documented known activating BRAF alteration.
  • Advanced Solid Tumor: locally advanced or solid tumor with documented known or expected to be activating RAF fusion.
  • Participants must have histopathologic verification of at either original diagnosis or relapse.
  • Must have received at least one line of prior systemic therapy and have documented evidence of radiographic progression.
  • Must have at least 1 as defined by RANO (Arms 1 \& 2) or v1.1 (Arm 3) criteria

Exclusion criteria

Exclusion Criteria:

  • Participant's tumor has additional previously-known activating molecular alterations.
  • Participant has symptoms of without radiographically recurrent or radiographically progressive disease.
  • Known or suspected diagnosis of neurofibromatosis type 1 (NF-1) via genetic testing or current diagnostic criteria.

Other inclusion/exclusion criteria as stipulated by protocol may apply

Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
141 participants (estimated)

Study arms

  • Experimental
    Arm 1: Low-Grade Glioma

    Participants with recurrent or progressive low-grade glioma will receive 420 milligrams/meters square (mg/m\^2) of tovorafenib weekly according to dose rounding guidelines and according to their baseline body surface area (BSA).

    Drug: Tovorafenib

  • Experimental
    Arm 2: Low-Grade Glioma Expanded Access

    Participants with recurrent or progressive low-grade glioma will receive 420 mg/m\^2 of tovorafenib weekly according to dose rounding guidelines and according to their baseline BSA.

    Drug: Tovorafenib

  • Experimental
    Arm 3: Advanced Solid Tumor

    Participants with advanced solid tumors will receive 420 mg/m\^2) of tovorafenib weekly according to dose rounding guidelines and according to their baseline BSA.

    Drug: Tovorafenib

Interventions

  • Tovorafenib is an oral Type II RAF kinase inhibitor available in 100 mg immediate-release tablet or 25 mg/milliliter (mL) powder for reconstitution.

    Also known as: DAY101

06

What researchers measure

Primary outcomes

  1. Arm 1: Overall response rate

    ORR is defined as percentage of participants with best overall confirmed response of complete response (CR) or partial response (PR) by the Response Assessment in Neuro-Oncology - high-grade glioma (RANO-HGG) criteria.

    Time frame: Up to 48 months

  2. Arm 2: Number of participants reporting adverse events

    An adverse event (AE) is any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.

    Time frame: Up to 48 months

  3. Arm 2: Number of participants with clinically significant changes in clinical chemistry parameters

    Time frame: Up to 48 months

  4. Arm 2: Number of participants with clinically significant changes in hematology parameters

    Time frame: Up to 48 months

  5. Arm 3: Overall response rate

    Determined by the treating investigator and measured by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 or RANO-HGG criteria, as appropriate.

    Time frame: Up to 48 months

Secondary outcomes

  1. Arm 1 and 3: Number of participants reporting adverse events

    An adverse event (AE) is any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.

    Time frame: Up to 48 months

  2. Arm 1 and 3: Number of participants with clinically significant changes in clinical chemistry parameters

    Time frame: Up to 48 months

  3. Arm 1 and 3: Number of participants with clinically significant changes in hematology parameters

    Time frame: Up to 48 months

  4. Arm 1: Area under the concentration-time curve (AUC) of Tovorafenib

    Time frame: Cycle 1: Day 1 and Day 15; Cycles 2, 4, 7, 10 and 13: Day 1

  5. Arm 1: Minimum drug concentration (Cmin)

    Time frame: Cycle 1: Day 1 and Day 15; Cycles 2, 4, 7, 10 and 13: Day 1

  6. Arm 1: Change from Baseline QT interval corrected for heart rate by Fridericia's formula (ΔQTcF)

    Time frame: Baseline to 48 months

  7. Arm 1: Change from Baseline PR interval (ΔPR)

    Time frame: Baseline to 48 months

  8. Arm 1: Change from Baseline QRS interval (ΔQRS)

    Time frame: Baseline to 48 months

  9. Arm 1: Change from baseline heart rate (ΔHR)

    Time frame: Baseline to 48 months

  10. Arm 1: Change in electrocardiogram (ECG) waveform morphology

    Time frame: Baseline to 48 months

  11. Arm 1 and Arm 2: Overall response rate

    ORR is defined as percentage of participants with best overall confirmed response of CR or PR by the RANO-HGG criteria.

    Time frame: Up to 48 months

  12. Arm 1, Arm 2 and Arm 3: Overall response rate in Pediatric participants

    ORR is defined as percentage of participants with best overall confirmed response of CR or PR or minor response (MR) by Response Assessment in Pediatric Neuro-Oncology (RAPNO) criteria.CR or PR by RECIST v1.1 criteria.

    Time frame: Up to 48 months

  13. Arm 1, Arm 2 and Arm 3: duration of progression-free survival (PFS)

    PFS as defined by the time following initiation of tovorafenib to progression or death in participants treated with tovorafenib measured by RECIST v1.1, RAPNO, or RANO-HGG criteria as determined by the treating investigator and an IRC.

    Time frame: Up to 48 months

  14. Arm 1, Arm 2 and Arm 3: Duration of response (DOR)

    DOR as defined by the length of response in participants with best overall confirmed response of CR or PR or MR and measured by RANO-HGG, RAPNO, and/or RECIST v1.1 criteria, as applicable.

    Time frame: Up to 48 months

  15. Arm 1, Arm 2 and Arm 3: Time to response (TTR)

    TTR as defined as the time to first response following initiation of tovorafenib in participants with best overall confirmed response of CR or PR measured by RECIST v1.1 or RANO-HGG criteria, as applicable.

    Time frame: Up to 48 months

  16. Arm 1, Arm 2 and Arm 3: Clinical benefit rate (CBR)

    CBR as defined as participants with BOR of CR, PR or stable disease (SD) measured by RECIST v1.1 or RANO-HGG, as applicable, and lasting 12 months or more following initiation of tovorafenib.

    Time frame: Up to 48 months

  17. Arm 1 and Arm 2: Duration of overall survival

    Overall survival as defined by the time following initiation of tovorafenib to death of any cause in participants treated with tovorafenib.

    Time frame: Up to 48 months

  18. Arm 1: Change from baseline in best corrected visual acuity (BCVA) outcomes

    Time frame: Baseline to 48 months

  19. Arm 1: Changes in molecular analysis of cells obtained from archival tissue

    Time frame: At Screening

07

Study locations

33 of 35 sites recruiting
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Apr 2021 (actual). Primary completion is estimated for May 2027, 73 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 3, 2021
First posted
Mar 1, 2021
StartActual
Apr 22, 2021
Primary completionEst.
May 31, 2027
CompletionEst.
May 31, 2027
Results delay requested
Dec 20, 2023
Last update
Apr 10, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 10, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04775485
Lead sponsor
Day One Biopharmaceuticals, Inc.
Collaborators
Pacific Pediatric Neuro-Oncology Consortium
Responsible party
Sponsor
First posted
Mar 1, 2021
Start date
Apr 22, 2021
Primary completion
May 31, 2027 (estimated)
Completion
May 31, 2027 (estimated)
Last update
Apr 10, 2025

Study contacts

Day One Biopharmaceuticals, Inc.
Contact
firefly-1@dayonebio.com
650-484-0899

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tovorafenib

Start the discussion